1De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
2Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
3Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
4De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
5De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
7Yutaka Yonemura M.D.,Takashi Fujimura M.D.,Sachio Fushida M.D.,Shigeru Takegawa M.D.,Toru Kamata M.D.,Kanji Katayama M.D.,Takeo Kosaka M.D.,Akio Yamaguchi M.D.,Kouichi Miwa M.D.,Ituo Miyazaki M.D.Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination[J].World Journal of Surgery.1991(4)
8Prof. Dr. Peter Schlag M.D.Adjuvant chemotherapy in gastric cancer[J].World Journal of Surgery.1987(4)
9J. W. L. Fielding F.R.C.S.,S. L. Fagg F.R.C.S.,B. G. Jones F.R.C.S.,D. Ellis F.R.C.S.,M. S. Hockey F.R.C.S.,A. Minawa Ph.D.,V. S. Brookes F.R.C.S.,J. L. Craven M.D., F.R.C.S.,M. C. Mason F.R.C.S.,A. Timothy M.R.C.P., F.R.C.R.,J. A. H. Waterhouse Ph.D.,P. F. M. Wrigley Ph.D., F.R.C.P.An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British stomach cancer group[J].World Journal of Surgery.1983(3)
10Lise M,Nitti D,Marcher A,Sahmoud T,Buyse M,Duez N,Fiorentino M,Santos JGD,Labianca R,Rougier P,Gignoux M.Final results of aphase Ⅲ clinical trial of adjuvant chemotherapy with the modified fluorouracil,doxorubicin,and mitomycin regimen in resectable gastric cancer[].Journal of Clinical Oncology.1995
4Sugarbaker PH, Cunliffe W J, Beliliveau J, et al. Rationale for interrating early postoperative intraperitoneat chemotherapy into the surgical treatment of gastrointestinal cancer[J]. Semin Oncol, 2006,36(1) :183.
5Takebayashi Y,Akiyama S,Natsugoe S,et al.The expression of multidrug resistance protein in human gastrointestinal tract carcinomas[J].Cancer,1998,82(4):661-666.
6Shi H,Lu D,Shu Y,et al.Expression of muhidrug-resistance related proteins P-glyeoprotein,glutathione-S-transferases,topoisomerase-Ⅱ and lung resistance protein in primary gastric cardiac adenocarcinoma[J].Cancer Invest,2008,26(4):344-351.
7Nooter K,Stoter G.Molecular mechanisms of muhidrug resistance in cancer chemotherapy[J].Pathol Res Pract,1996,192(7):768-780.
8Hu WQ,Peng CW,Li Y.The expression and significance of Pglycoprotein,lung resistance protein and muhidrug resistance associated protein in gastric cancer[J].J Exp Clin Cancer Res,2009,28(3):144-149.
9Sauna ZE,Kim IW,Ambudkar SV,et al.Genomics and the mechanism of P-glycoprotein (ABCB1)[J].J Bioenerg Biomembr,2007,39(5-6):481-487.
10Wang W,Liu G,Zheng J,et al.Human renal UOKI30 tumor cells:a drug resistant cell line with highly selective over expression of glutathione S-transferase-pi isozyme[J].Eur J Pharmacol,2007,568(1-3):61-67.
